What do systematic reviews say?

Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Phamacotherapies that specifically target ammonia vs placebo or non‐absorbable disaccharides

The review found no eligible studies for this question.

• Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  450 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1870 participants
  Very low

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1129 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1772 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 156 participants
  Very low

Non‐platinum therapies vs platinum combination

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  GRADE not reported

Interferon‐α combined with targeted therapies vs standard targeted therapies

The review found no eligible studies for this question.

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Targeted immunotherapy alone vs standard targeted therapies

Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  RR 1.51 [1.28, 1.78]
  1 study · 704 participants
  Moderate
• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  RR 1.37
  1 study · 703 participants
  Moderate

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Interferon‐α plus bevacizumab vs standard targeted therapies

The review found no eligible studies for this question.

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vaccine treatment vs standard therapies

The review found no eligible studies for this question.

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CBT vs ALL OTHER PSYCHOLOGICAL THERAPIES

• Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low

Trazodone vs placebo

The review found no eligible studies for this question.

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Orexin antagonists vs placebo

The review found no eligible studies for this question.

• Pharmacotherapies for sleep disturbances in dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found